Severe adverse reactions associated with quetiapine

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Degner, Detlef ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; PLACEBO; QUETIAPINE; ANTIDEPRESSANT AGENT; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADVERSE OUTCOME; AGE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG METABOLISM; GALACTORRHEA; GYNECOMASTIA; HEALTH CARE COST; HUMAN; LETTER; MAJOR DEPRESSION; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QT PROLONGATION; RISK BENEFIT ANALYSIS; SEIZURE; SEROTONIN SYNDROME; WITHDRAWAL SYNDROME; CHEMICALLY INDUCED; DEPRESSIVE DISORDER, MAJOR; DYSLIPIDEMIA; HYPERGLYCEMIA; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DYSLIPIDEMIAS; HUMANS; HYPERGLYCEMIA; WEIGHT GAIN;

EID: 84926316118     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h1575     Document Type: Letter

References (5)

1. Pringsheim T, Gardner D, Patten SB. Adjunctive treatment with quetiapine for major depressive disorder: are the benefits of treatment worth the risks? BMJ 2015;350:h569. (4 March.)
2. Asmal L, Flegar SJ, Wang J, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2013;11:CD006625.
3. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62.
4. Degner D, Nitsche MA, Bias F, et al. EEG alterations during treatment with olanzapine. Eur Arch Psychiatry Clin Neurosci 2011;261:483-8.
5. Kim DR, Staab JP. Quetiapine discontinuation syndrome. Am J Psychiatry 2005;162:1020.